Author

Benoît Grellier

Observed names: B. Grellier, Benoit Grellier, Grellier, B.

Observed institution: Transgene (France)

OpenAlex ID: A5043271150

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

2017 · Caroline Tosch, Bérangère Bastien, et al. · Journal for ImmunoTherapy of Cancer · 73

A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells

2013 · Hélène Haegel, Christine Thioudellet, et al. · mAbs · 39

PDF

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency

2018 · Marine Ricordel, Johann Foloppe, et al. · Cancers · 24

PDF

Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.

2023 · Christian H.H. Ottensmeier, Jean-Pierre Delord, et al. · Journal of Clinical Oncology · 11

3D modeling and characterization of the human CD115 monoclonal antibody H27K15 epitope and design of a chimeric CD115 target

2014 · Benoît Grellier, Benoît Grellier, et al. · mAbs · 11

PDF

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).

2022 · Jean-Pierre Delord, Matthew Stephen Block, et al. · Journal of Clinical Oncology · 9

Abstract 288: TG3003, an immunomodulatory anti-CD115 mAb targeting M2-macrophage polarization in the tumor microenvironment

2015 · Hélène Haegel, Christelle Ziller-Remy, et al. · Cancer Research · 2

A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial

2026 · Christian Ottensmeier, Jean-Pierre Delord, et al. · Nature Communications · 1

PDF

385P VacDesignR®: A computational tool to optimize viral-based individualized neoantigen therapeutic vaccine production

2025 · B. Grellier, N. Silvestre, et al. · ESMO Real World Data and Digital Oncology · 1

Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

2023 · Ana Lalanne, Camille Jamet, et al. · Cancer Research · 1

Abstract CT182: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

2022 · Matthew S. Block, Jean-Pierre Delord, et al. · Cancer Research · 1

Abstract 4566: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

2020 · Brandon Malone, Caroline Tosch, et al. · Cancer Research · 1

Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties

2026 · Aimeric Agaoua, Camille Rey, et al. · Frontiers in Bioengineering and Biotechnology

PDF

A chimeric oncolytic poxvirus overcomes barriers to systemic cancer virotherapy

2026 · Philippe Erbs, Johann Foloppe, et al. · Research Square

PDF

Synthetic Genome Shuffling of Poxviruses through Yeast for Next-Generation Oncolytic Platforms

2026 · A. Agaoua, C. Rey, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial

2026 · C. Ottensmeier, J-P. Delord, et al. · medRxiv

PDF

In vivo preclinical low field MRI monitoring of tumor growth following a suicide gene therapy in an orthopic mice model of human glioblastoma

2010 · Breton, E., Goetz, C., et al. · HAL

Works count: 18

Citation count: 185

H-index: 7

I10-index: 6